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Background: In a previously published report we characterized the expression of the metastasis-associated
proteins S100A4, osteopontin (OPN) and ephrin-A1 in a prospectively collected panel of non-small cell lung cancer
(NSCLC) tumors. The aim of the present follow-up study was to investigate the prognostic impact of these potential
biomarkers in the same patient cohort. In addition, circulating serum levels of OPN were measured and single
nucleotide polymorphisms (SNP) in the −443 position of the OPN promoter were analyzed.
Methods: Associations between immunohistochemical expression of S100A4, OPN and ephrin-A1 and relapse free
and overall survival were examined using univariate and multivariate analyses. Serum OPN was measured by ELISA,
polymorphisms in the −443 position of the tumor OPN promoter were analyzed by PCR, and associations between
OPN levels and promoter polymorphisms and clinicopathological parameters and patient outcome were investigated.
Results: High expression of OPN in NSCLC tumors was associated with poor patient outcome, and OPN was a strong,
independent prognostic factor for both relapse free and overall survival. Serum OPN levels increased according to
tumor pT classification and tumor size, and patients with OPN-expressing tumors had higher serum levels than patients
with OPN-negative tumors. S100A4 was a negative prognostic factor in several subgroups of adenocarcinoma patients,
but not in the overall patient cohort. There was no association between ephrin-A1 expression and patient outcome.
Conclusions: OPN is a promising prognostic biomarker in NSCLC, and should be further explored in the selection of
patients for adjuvant treatment following surgical resection.
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Lung cancer, with non-small cell lung cancer (NSCLC)
constituting 85% of cases, retains its position as one of
the most commonly diagnosed cancer forms globally.
In fact, lung cancer is the leading cause of cancer death in
men, and the second leading cause of cancer death in
women [1]. The overall 5-year survival rate for NSCLC is
poor, and even for patients with early stage disease who
undergo curatively intended surgery, the post operative re-
currence rate is high compared to other types of cancer [2].
Nearly half of NSCLC patients undergoing surgical resec-
tion experience disease relapse, and in these patients* Correspondence: ane.kongsgaard.rud@rr-research.no
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reproduction in any medium, provided the ordisease stage according to TNM, followed by age and gen-
der, are the most important prognostic factors [3]. However,
even in patients with early stage NSCLC there are substan-
tial differences in recurrence rates, reflecting the biological
heterogeneity and complexity of these tumors. As the cur-
rent TNM staging does not provide satisfactory prognos-
tication of the patients, it is essential to identify novel
prognostic biomarkers and determine if they are applicable
in the subclassification of patients. Also, novel therapies in
NSCLC are certainly warranted, and as targeted treatment
is becoming increasingly important, identifying molecular
markers as potential therapeutic targets is necessary.
In a prospectively collected panel of tumor tissue from
244 NSCLC patients undergoing curatively intended sur-
gery, we have previously characterized the expression of
the metastasis-associated proteins S100A4, osteopontin
(OPN) and ephrin-A1, and investigated the associations. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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parameters [4]. S100A4, a member of the S100 protein
family, is involved in several steps of the metastatic cas-
cade and is associated with patient outcome in various
types of cancer [5]. In NSCLC, several studies have shown
S100A4 to be related to poor prognosis [6-8], whereas
others have reported no association between S100A4 and
patient outcome [9,10]. OPN, a multifunctional protein
secreted by a variety of cells [11], is associated with cancer
development, progression and metastasis in different ma-
lignancies, including NSCLC [12-17]. Circulating plasma
OPN levels in NSCLC patients have been shown to cor-
relate with disease stage [16,18] and with survival [19,20].
OPN can undergo extensive post-translational modifica-
tions and alternative RNA splicing [11], and polymorphisms
in the OPN promoter have been shown to affect its tran-
scriptional activity [18,21].
Being a ligand for several of the Eph family receptor
tyrosine kinases, the cell surface protein ephrin-A1 is in-
volved in multiple biological processes including metastasis
and tumor angiogenesis [22]. In lung cancer however, re-
sults are conflicting, as high expression has also been asso-
ciated with favorable prognostic factors in NSCLC [2] and
improved overall survival in lung adenocarcinoma [23].
In our previously published report we showed that
S100A4, OPN and ephrin-A1 were highly expressed in
NSCLC tumor tissue, and that S100A4 expression was
associated with adenocarcinoma histology, as well as
with small tumor size and high degree of differentiation.
S100A4, OPN and ephrin-A1 are all potentially interest-
ing biomarkers that may have clinical impact in NSCLC,
and in this follow-up study we investigate the association
between the expression of these proteins and patient
outcome in the previously described cohort. In addition,
pre-surgery serum OPN levels were measured and single
nucleotide polymorphisms (SNP) in the −443 position of
the OPN promoter were analyzed. The potential relation-
ships between OPN promoter polymorphism, expression in
primary tumor biopsies and circulating levels of OPN were
investigated, and assessed in relation to patient outcome.
Methods
Patient cohort
Between March 2006 and April 2010, primary tumor
samples were prospectively collected from 244 patients
with assumed or verified NSCLC who underwent cura-
tively intended surgical resection at Rikshospitalet, Oslo
University Hospital, Oslo, Norway. The study was ap-
proved by the Regional Ethics Committee (S-06402b),
and written informed consent was obtained from all pa-
tients. Resected tissue was processed for routine histo-
pathological assessment, and histological examination of all
tissue specimens was performed by an experienced path-
ologist. Tumors were staged according to the InternationalAssociation for the Study of Lung Cancer (IASLC), TNM 7,
and the histological subtypes were classified according
to WHO criteria. Thirty-four patients were excluded
from the statistical analyses for the following reasons:
histology other than NSCLC (carcinoid (12), small cell
lung cancer (4), lung metastases from other primary
cancer (7)), metastatic disease at the time of surgery (3),
inadequate surgical margins (4), and withdrawal of con-
sent (4). The study population thus included 210 pa-
tients with histologically verified primary NSCLC in
pTNM stage I-III who had undergone curatively intended
surgery. Postoperatively, patients were followed by clinical
evaluation and radiological examination (CT or conven-
tional x-ray of the chest) in their respective local hospitals
according to national guidelines. Follow-up data were ob-
tained from these hospitals and by contacting the patient’s
general practitioner. In addition, survival data were ob-
tained from the National Registry of Norway and updated
on August 14th 2012.
Tissue microarray (TMA) construction and
immunohistochemistry
The tissue microarray construction and the immunohisto-
chemical staining procedures have been described in detail
previously [4]. Briefly, the most representative tumor areas
in each tumor tissue donor block were selected and marked
on hematoxylin-eosin stained sections, and at least two
cores from different tumor areas of the same specimen
were included in the TMA. TMA sections were con-
structed using a tissue arrayer instrument (Beecher Instru-
ments, Silver Springs, MD, USA). Immunohistochemical
staining was done using the EnVision™ FLEX+ detection
system (Dako, Glostrup, Denmark) for S100A4 and OPN,
and the EnVision + system (Dako) for ephrin-A1. The fol-
lowing primary antibodies were used: mouse monoclonal
anti-S100A4 (20.1) [24], final concentration 3 μg/ml, rabbit
polyclonal anti-osteopontin 0.67 μg/ml (Rb-9097, Thermo
Fisher Scientific, Fremont, CA, USA) and rabbit polyclonal
anti-ephrin-A1 0.67 μg/ml (sc-911, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA). For positive controls, sections
from colorectal tumor tissue, ovarian tissue and cervical
portio biopsy tissue known to express high amounts of
S100A4, OPN and ephrin-A1, respectively, were used. In-
formation regarding the evaluation of the immunohisto-
chemical staining has been reported in Rud et al. [4]. In
brief, for S100A4 cytoplasmic and nuclear immunoreactiv-
ity was recorded. The samples were scored using a 0–3
scale according to staining intensity, with 0 denoting nega-
tive (no staining), 1 denoting weak staining, 2 intermediate
staining and 3 strong staining. For nuclear staining, the
fraction of positively stained nuclei was estimated (0 = 0%,
1 = < 1%, 2 = 1 – 10%, 3 = 11 – 33%, 4 = 34 – 66% and 5 =
67 – 100%). All samples with >10% stained nuclei (score ≥
3) were considered positive, and grouped according to
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staining in the cytoplasm and in the nucleus, and for that
reason data analyses for nuclear S100A4 staining individu-
ally did not provide further information. The negative and
weakly stained S100A4 cases were pooled into one group
for the statistical analyses. OPN and ephrin-A1 cytoplasmic
immunoreactivity was scored according to a 0–2 scale, with
0 defined as negative (no staining), 1 as intermediate stain-
ing and 2 as strong staining.
Measurement of serum OPN concentration
The OPN levels in serum were measured with the
ELISA kit Quantikine Human Osteopontin Immunoassay
DOST00 from R&D (R&D Systems Inc., Minneapolis,
Minnesota, USA), according to the manufacturer’s man-
ual. In brief; serum samples from each patient were di-
luted 1:10 with calibrator Diluent RD5-24 and incubated
in an OPN antibody-coated micro titer plate for 2 hours
at room temperature. After washing the wells four times,
200 μl OPN conjugate (polyclonal antibody against OPN
conjugated to horseradish peroxidase) was added to each
well and incubated for 2 hours at room temperature.
Following four washes, 200 μl substrate solution (hydro-
gen peroxide and chromogen) was added to each well
and incubated for 30 minutes at room temperature. The
samples were measured on a plate reader Victor 1420
Multilabel Counter, (Wallac/PerkinElmer Life Sciences,
Turku, Finland) at 450 nm with wavelength correction
at 570 nm. Standard curve and sample values were cal-
culated by use of the Wallac MultiCalc program.
Analysis of polymorphisms in the OPN promoter
For analysis of the −443 OPN promoter polymorphism
(rs17730582) in primary NSCLC, total DNA was isolated
from 210 tumor specimens using Maxwell 16 DNA Puri-
fication Kit (Promega, Madison, WI, USA) according to
the manufacturer’s manual. A fluorescently marked frag-
ment of the OPN gene containing the SNP rs 11730582
was amplified by PCR. The PCR reaction consisted of 50
ng genomic DNA, 0.08 U/μl Taq, polymerase, 0.005 U/μl
PFU polymerase, 1× Buffer 4 (ABgene), 3 mM MgCl2, and
0.4 mM dNTP mix (ABgene) and 0.2 μM of the primer
(5’-Fam-CGCCCGCCGCGCCCCGCGCCCGTCCGCCG
kit Quantikine Human OCCCCCGCCCGGGAGCTTGA
GTAGTAAAGGACA-3’) and 0.3 μM of the primer (5’A
GAATGGTCCTGCACCAGTAA3’). Temperature cycling
was performed in a DNA Engine Tetrad 2 Thermal Cycler
(Biorad, CA, USA) using the following cycling conditions:
denaturation 5 min at 95°C, followed by 35 cycles of 95°C
in 30 s, annealing 57°C in 30s and 72°C in 60s. For variant
detection amplified 6-fam labelled PCR products were
analyzed by denaturant capillary electrophoresis in a Mega-
BACE 1000 DNA Analysis System (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden). The base variants wereseparated by cycling temperature capillary electrophoresis
(CTCE), with mean separating temperatures of 52,5°C and
amplitudes of 3°C cycled 20 times. The variants were
identified by co-analysis with a mutated internal stand-
ard in a similar manner as previously described by
Bjørheim et al. [25].
Statistical analyses
Univariate survival analysis was performed according to
the Kaplan-Meier method, and the log rank test was
used to evaluate the statistical significance between sur-
vival curves. Multivariate survival analysis was performed
using the Cox proportional hazard regression model with
backward, stepwise elimination of variables. Relapse free
survival was calculated from the date of surgery until the
date of diagnosis of local recurrence or metastasis, or until
the date of the last follow-up visit for healthy patients.
Median follow-up for patients still alive who had not de-
veloped metastasis or local recurrence was 34.0 months
(range 12.5 – 52.9 months). Overall survival was measured
from date of surgery until date of death. Associations
between OPN promoter −443 genotypic variations and
immunohistochemical expression were examined using
linear by linear association chi-square test. For analyses of
associations between serum OPN levels and clinicopatho-
logical parameters, parametric tests (independent samples
t-test or one-way ANOVA, as appropriate) were used. All
data analyses were performed using SPSS statistical soft-
ware version 18.0 (SPSS Inc., Chicago, IL, USA), and p-
values < 0.05 were considered statistically significant.
Results
Patient characteristics and outcome
Clinicopathological parameters and outcome parameters
of the study cohort are summarized in Table 1. The
mean patient age was 65 years (range 43–82) for women
and 67 years (range 39 – 83) for men. The NSCLC tumors
included 61% adenocarcinomas, 28% squamous cell car-
cinomas and 11% large cell carcinomas. Sixty-four percent
of the patients were in pTNM stage I, 21% of patients in
pTNM II, and 15% in pTNM stage III. Adjuvant chemo-
therapy was administered in 66 cases (31%), and 5 patients
(2%) received postoperative radiotherapy. Sixty four pa-
tients (31%) presented disease relapse (local recurrence or
metastases) during follow-up. A total of 70 (33%) patients
had died at the end of follow-up.
Associations between clinicopathological parameters and
patient outcome
The prognostic significance of conventional clinicopatho-
logical variables was first investigated by univariate ana-
lysis and the results are presented in Table 2. Tumor size
> 3.0 cm and poor tumor differentiation (grade 3) were
significantly associated with disease relapse (p = 0.04 and
Table 1 Characteristics of patient cohort
Parameter Patients
Number Percent
Gender Male 114 54
Female 96 46
Histology Adenocarcinoma (incl. BAC) 128 61
Squamous cell carcinoma 58 28
Large cell carcinoma 24 11
Differentiation G1 (well differentiated) 20 10
G2 (moderately differentiated) 135 68
G3 (poorly differentiated) 43 22
Missing 12
pTNM I 135 64
II 43 21
III 32 15




pN 0 153 73
1 38 18
2 19 9
Tumor size ≤ 2.0 cm 56 27
2.1 – 3.0 cm 61 29
3.1 – 5.0 cm 64 30
5.1 – 7.0 cm 23 11
> 7.0 cm 6 3
Metastasis* Yes 55 26
No 155 74
Local recurrence Yes 24 11
No 186 89
Death Yes 70 33
No 140 67
*Metastasis during the follow-up period.
Table 2 Univariate survival analysis of clinicopathological
parameters and OPN
Relapse free survival Overall survival
Parameter p* HR 95% CI p* HR 95% CI
Gender 0.67 0.48
Female
Male 0.9 0.6–1.5 1.2 0.7–1.9
Age 0.81 0.05
< 65 years
> 65 years 1.1 0.6–1.7 1.6 1.0–2.7
Histology 0.91 0.08
Adenocarcinoma (incl.BAC)
Squamous cell carcinoma 1.0 0.6–1.8 1.7 1.0–2.9
Large cell carcinoma 1.2 0.6–2.4 1.6 0.8–3.1
pTNM 0.28 0.97
I
II 1.2 0.7–2.2 1.0 0.5–1.8
III 1.4 0.7–2.7 1.0 0.5–2.1
pT 0.26 0.74
pT1
pT2 1.1 0.6–2.0 1.3 0.8–2.3
pT3 1.4 0.6–3.4 0.9 0.3–2.4
pT4 1.8 0.6–5.2 1.2 0.4–4.2
pN 0.18 0.27
pN0
pN1–2 1.4 0.8–2.4 1.3 0.8–2.2
Tumor size 0.04 0.04
≤ 3.0 cm
≥ 3.1 cm 1.7 1.0–2.7 1.6 1.0–2.6
Differentiation 0.03 0.01
G1 (well)
G2 (moderate) 2.4 0.7–7–6 2.5 0.8–8.0
G3 (poor) 3.5 1.0–11.9 3.9 1.2–13.4
Osteopontin 0.005 0.04
0
1 2.0 0.9–4.5 1.2 0.6–2.4
2 3.9 1.5–10.4 2.7 1.2–6.3
*p-values calculated by log rank test.
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0.01, respectively). Differences in relapse free survival were
observed for pTNM stage I – III and lymph node involve-
ment status, but these were not statistically significant. Pa-
tients < 65 years had a better overall survival (p = 0.05).
None of the other parameters showed a statistically sig-
nificant correlation with patient outcome. Multivariate
analyses were performed including the following parame-
ters; age, gender, histology, tumor size and differentiation,
and only tumor size was significantly associated with re-
lapse free survival (p = 0.008, hazard ratio (HR) 1.2; 95%
confidence interval (CI) 1.1-1.4; data not shown).Associations between S100A4 and ephrin-A1 expression
and patient outcome
The immunohistohemical staining pattern and distribution
of OPN, S100A4 and ephrin-A1 in the tumor tissues have
been described previously [4]. Five patients from the previ-
ous cohort were not included in the present analysis, and
Table 3 gives an overview of the immunohistochemical ex-
pression in the present cohort. As shown in Figure 1A,
there were no significant differences in relapse free survival

















Figure 1 Kaplan-Meier survival plots depicting relapse free survival (A
expression of S100A4 (A, D), ephrin-A1 (B, E) and OPN (C, F).
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S100A4 expressing tumors. We found a tendency for
worse overall survival in S100A4-positive patients, and to
explore this further we performed statistical analyses with
only two groups; tumors with strong S100A4 staining were
categorized as positive and the remaining tumors were cat-
egorized as negative. S100A4-positive patients had poorer
overall survival, however the difference did not reach stat-
istical significance (p = 0.09). Similar observations were
seen when we analyzed the adenocarcinoma patients as a
separate group. A better, yet not statistically significant,
overall survival was seen for patients with S100A4-negative
tumors (p = 0.06). When patients were stratified by disease
stage, S100A4 was associated with poor outcome in pTNM
I (p = 0.04). S100A4 was also a negative prognostic factor
in lymph node negative patients, where 3-year overall sur-
vival for patients with S100A4-positive and negative tu-
mors was 56% and 83%, respectively (p = 0.01).
Further subgroup analyses of the overall cohort were
performed and showed that in patients with pT2 tumors,
S100A4 expression was a significant negative prognostic
factor for relapse free and overall survival (p = 0.03 andC
F
-C) and overall survival (D-F) based on immunohistochemical
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free survival for S100A4-positive patients in this group
was 45%, compared to 71% for S100A4-negative patients.
Ephrin-A1 was not a significant prognostic marker in this
patient cohort (Figure 1B and 1E) and no prognostic im-
pact was revealed when performing subgroup analyses.
Association between OPN expression and patient outcome
Representative images of the immunohistochemical ex-
pression of OPN are shown in Additional file 1: Figure S1.
The expression of OPN was strongly associated with poor
relapse free survival (p = 0.005, Figure 1C and Table 2).
Patients with high OPN expression in the tumor (12% of
cases) had a 3-year relapse free survival rate of 39%, com-
pared to 64% for patients with moderate OPN expression
(65% of the patients) and 83% for patients whose tumors
were negative for OPN. A similar trend was found for
overall survival, where 3-year survival rates for high, mod-
erate and low expression of OPN was 38%, 70% and 71%,
respectively (p = 0.04, Figure 1F). Furthermore, subgroup
analysis of only stage I-II patients were performed and
showed that OPN expression was significantly associated
with both relapse free survival (p = 0.01, Figure 2A) and
overall survival (p = 0.04, data not shown). Stratification
of the patients according to histological subtype revealed
a prognostic impact of OPN in adenocarcinoma patients
(p = 0.02, Figure 2B). To determine if the relationship be-
tween OPN expression and patient outcome was inde-
pendent of other clinical and pathological parameters,
multivariate analyses including the following parameters
were performed: OPN, age, gender, pT category, pN cat-
egory, tumor differentiation and histology. Interestingly,
OPN was independently and significantly associated with
both relapse free survival (p = 0.02, HR 3.9; 95% CI 1.5-
10.4; for strong OPN staining compared to negative stain-
ing; data not shown) and overall survival (p = 0.05; HR 2.8;
95% CI 1.2-6.5; for strong OPN staining compared to
negative staining; data not shown).
Measurement of serum OPN concentration
Since immunohistochemical expression of OPN was as-
sociated with poor outcome, we investigated if serum
levels of OPN could reflect expression in the primary
tumor and be of prognostic significance. Serum samples
for measurement of circulating OPN were available from
201 of the 210 patients, and OPN concentrations ranged
from 8.1 to 164.1 ng/ml, with a mean level of 36.6 ng/ml
and a median value of 32.9 ng/ml. OPN was also mea-
sured in serum samples from a control group of 30
healthy individuals (blood donors), where the mean level
was 22.9 ng/ml and the median value 20.3 ng/ml (range
9.5 – 49.1 ng/ml). The difference in serum levels between
the patients and the donors was statistically significant (p <
0.001, independent samples t-test). Associations betweenserum OPN concentrations and clinicopathological param-
eters of the patient cohort are summarized in Table 4. Cir-
culating OPN levels were higher in male patients compared
to female patients (p = 0.02). Small differences in concen-
tration according to pTNM stage were observed, but these
were not statistically significant. However, OPN levels were
significantly associated with both pT classification and
tumor size (p = 0.006 and 0.01, respectively; Table 4). In
fact, the median OPN concentration in patients with pT1
tumors was 28.0 ng/ml, compared to 33.9 for pT2, 35.2 for
pT3 and 39.6 for pT4. Among the histological subtypes,
patients with large cell carcinomas and squamous cell car-
cinomas had higher OPN levels than adenocarcinoma
patients, but the difference did not reach statistical signifi-
cance (Table 4).
No statistically significant association was found be-
tween serum OPN concentrations and OPN expression
in the primary tumor (p = 0.09), but patients with high
OPN expression had numerically higher serum levels
than patients with OPN-negative tumors (median values
of 37.0 ng/ml and 31.0 ng/ml, respectively). However, a
direct comparison between serum levels and immuno-
histochemical expression without taking the size of the
tumor into account might not be relevant, as larger tu-
mors would be expected to secrete more OPN than
small tumors given the same OPN expression levels.
Tumor diameter measured in one dimension was the
only parameter available describing tumor size in this
study. Even though this is an imperfect surrogate of tumor
volume, we found that OPN serum levels divided by tumor
diameter was closely associated with OPN expression in
the primary tumor. Patients with OPN-negative tumors
had a relative median serum level of 9.9 ng/ml, compared
to 10.8 and 15.6 ng/ml in patients with moderate and
strong expression, respectively (p = 0.005, Figure 2C).
In Cox univariate analysis the total serum OPN levels
were not associated with overall survival (p = 1.0; HR
1.0; 95% CI 0.99-1.01) or relapse free survival (p = 0.7;
HR 0.9; 95% CI 0.9-1.0, data not shown). In addition,
there was no correlation to relapse free survival (p = 0.42,
Figure 2D) or overall survival (p = 0.37, data not shown)
when using log-rank tests with patients dichotomized into
two groups at the median serum concentration. Survival
analyses were also performed with patients divided into
tertiles and quartiles according to serum OPN concentra-
tion without revealing any associations with outcome.
Analysis of polymorphisms in the −443 position of
OPN promoter
Polymorphisms in the −443 position of the OPN pro-
moter were analyzed in available tumor DNA from 174
patients in the cohort. Overall 101 samples (58%) were
heterozygous (−443C/T), 40 (23%) were homozygous for
CC and 33 samples (19%) were homozygous for TT.
AC D
B
Figure 2 Associations between osteopontin expression, serum concentrations and patient outcome. A and B: Kaplan-Meier survival plots
depicting relapse free survival based on tumor expression levels of OPN in the subgroup of patients with pTNM stage I and II (A) and in the
subgroup of patients with adenocarcinomas (B). C: Box plots showing relative serum OPN concentrations according to tumor OPN expression
levels. Since larger tumors are expected to secrete more OPN than small tumors given the same OPN expression levels, the serum OPN
concentrations have been divided by tumor diameter. Data show median values (horizontal line within the box) and interquartile range (upper
and lower border of the box) of serum OPN concentrations. The upper and lower horizontal bars represent the maximum and minimum values,
respectively. Outliers have been removed from the plot. D: Kaplan-Meier survival plot depicting relapse free survival based on serum OPN level,
patients dichotomized at the median OPN level. P-values calculated by one-way ANOVA test (C) and log-rank test (A, B, D).
Rud et al. BMC Cancer 2013, 13:540 Page 7 of 10
http://www.biomedcentral.com/1471-2407/13/540There was no association between the genotype and the
level of OPN expression in the tumors (p = 0.4, data not
shown) or between genotype and serum OPN concen-
trations (p = 0.2, data not shown). Also, OPN promoter
polymorphism did not affect the outcome of the patients
for either relapse free survival or overall survival (p = 0.8
and 0.9, respectively, data not shown).
Discussion
In the present prospective study we have investigated the
prognostic impact of OPN, S100A4 and ephrin-A1 in a
previously described cohort of 210 surgically resected
NSCLC patients [4]. We have shown that tumor OPN
expression is a strong predictor of poor prognosis, andmultivariate analysis confirmed OPN as an independent
prognostic factor. OPN plays an important role in tumori-
genesis, progression and metastatic dissemination in sev-
eral cancer types including NSCLC [15], and our results
are in line with previous studies on OPN expression in
NSCLC [13-15,17]. The present study is strengthened by
the fact that the patients have been prospectively recruited
and the cohort is therefore unbiased. Furthermore, this is
to our knowledge the first report investigating tumor OPN
expression levels, serum levels and genotypic variations in
the OPN promoter in NSCLC in the same patient cohort.
The finding that patients with OPN-expressing tumors
have worse relapse free and overall survival than patients
with OPN-negative tumors indicates that OPN has the
Table 4 Associations between patient characteristics by
serum OPN concentration




Female 27.9 ng/ml (18.6)
Male 35.2 ng/ml (19.5)
Age 0.41
< 65 years 32.8 ng/ml (17.8)
> 65 years 33.3 ng/ml (24.4)
Histology 0.17
Adenocarcinoma 30.1 ng/ml (18.7)
Squamous cell carcinoma 35.0 ng/ml (21.3)
Large cell carcinoma 39.7 ng/ml (23.2)
pTNM 0.42
I 31.0 ng/ml (20.7)
II 35.8 ng /ml (16.9)
III 35.2 ng/ml (22.2)
pT 0.006
pT1 28.0 ng/ml (25.2)
pT2 33.9 ng/ml (22.7)
pT3 35.2 ng/ml (21.7)
pT4 39.6 ng/ml (18.6)
pN 0.79
pN0 31.8 ng/ml (22.7)
pN1 35.4 ng/ml (15.6)
pN2 32.9 ng/ml (26.6)
Tumor size 0.01
≤ 3.0 cm 29.1 ng/ml (17.9)
≥ 3.1 cm 36.0 ng/ml (19.3)
*p-value calculated by one-way ANOVA test or independent samples t-test
as appropriate.
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According to national guidelines, patients in pTNM stage
II or III who are under 70 years should be offered adjuvant
chemotherapy following surgery. We found that in this
group, OPN-negative patients showed a particularly good
outcome, as their 3-year relapse free survival was similar to
stage I patients below 70 years (who are not offered adju-
vant chemotherapy). Also, in the latter group, the patients
with OPN-positive tumors showed a particularly poor out-
come. Consequently, OPN expression, if validated in future
studies, could be used for selection of patients for adjuvant
treatment following surgical resection of NSCLC.
Former studies have shown that also circulating OPN
levels in serum or plasma are increased in patients with
various forms of cancer, including NSCLC [16], and that
increased level is associated with poor prognosis [19,20].In the present patient cohort we found a median serum
OPN level of 32.9 ng/ml, which is comparable to results
from previous studies on OPN in serum [19] or plasma
[18,26]. Serum values of OPN are known to be signifi-
cantly lower than plasma values due to proteolytic cleavage
by thrombin during coagulation, and in our experience the
serum concentrations are approximately half of plasma
concentrations. We showed that there is a relationship be-
tween serum OPN levels and tumor OPN expression, as
patients with OPN-expressing tumors had higher serum
levels than patients with OPN-negative tumors, and this
difference became significant when tumor size was taken
into account. Furthermore, this study showed that serum
OPN levels increased according to pT classification and
tumor size, however there was no association to patient
outcome.
The finding that tumor OPN expression, but not serum
OPN level, was associated with poor survival may be ex-
plained by the multi-functionality of OPN. The majority
of the activities of OPN have been ascribed the interaction
between secreted OPN and its receptors on target cells
[27], however OPN is also found intracellularly and the
nonsecreted form is involved in cellular processes such as
migration and motility [27,28]. Our results may indicate
that the intracellular levels of OPN are more important
than the secreted circulating levels in NSCLC. Moreover,
variations in serum OPN measurements may occur due to
proteolytic cleavage of circulating OPN [29]. Finally, OPN
has an important role in inflammation and wound healing
[26], and therefore other systemic sources than the tumor
itself may affect OPN levels in the circulation.
There are several polymorphic sites in the regula-
tory element of the OPN promoter, and SNPs at nu-
cleotide −443 are frequently detected and reported
involved in regulation of OPN expression in normal
cells [18,21] as well as in cancer cells [30,31]. When
analyzing the genotypic variations at position −443 in
NSCLC tumor DNA we found no association to the ex-
pression levels of OPN at the protein level. The heterozy-
gous -443 T/C was the most common variant, however in
our material this polymorphism does not seem to be re-
sponsible for the different expression levels of OPN in the
tumors. Notably, the literature on this matter is conflicting
as it has been reported that melanoma metastases homo-
zygous for the -443C allele expressed higher levels of
OPN [31], but another study on hepatocellular carcinoma
showed an association between the -443TT genotype and
increased expression of OPN [30]. A recently published
study on advanced NSCLC patients reported that patients
with the -443CC genotype in their genomic DNA had sig-
nificantly lower survival rates than patients with the two
other genotypes [32].
S100A4 has been related to poor patient outcome in
several cancer types [5]. In our previously published report
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smaller, highly differentiated NSCLC tumors and that
S100A4 had a significantly higher expression in adenocar-
cinomas compared to the other histological subtypes [4].
In this group of patients, S100A4 expression was higher in
pTNM stage I than in stage II - III, and in lymph node
negative compared to lymph node positive patients. These
results were unexpected, and could be indicative of S100A4
as a positive prognostic factor in the examined patient co-
hort. However, in the present follow-up study we found a
tendency for shorter survival time in patients with S100A4-
positive tumors, although the difference was not statistically
significant. Subgroup analyses showed that S100A4 was as-
sociated with unfavourable prognosis in patients with pT2
tumors. In addition, in the adenocarcinomas, S100A4 had
negative prognostic impact also in stage I and in lymph
node negative patients. These results are consistent with
several previous reports on S100A4 in NSCLC [6-8], and
further suggest that S100A4 is a negative prognostic factor
in early-stage NSCLC, and especially in lung adenocarcin-
oma. In the present study there was no association between
ephrin-A1 expression and patient outcome. Previous stud-
ies on ephrin-A1 in NSCLC have been conflicting, as asso-
ciations to improved patient outcome have been reported
[2,23], while upregulation of the ephrin-A1 receptor EphA2
has also been related to poor clinical outcomes in many
types of cancer [2].
pTNM stage is considered to be the most important
prognostic factor in NSCLC [3], but in our cohort no
statistically significant association between pTNM stage
and survival was detected. The numbers of patients with
stage II, and especially stage III disease, were relatively small
compared to stage I, and this may have affected the statis-
tical analysis. Also, stage III NSCLC patients represent a
heterogenous group in which the optimal treatment differs
according to the T and N stage. As our cohort includes only
patients who were considered operable and underwent cu-
ratively intended surgery, the fact that these patients
present better outcome than stage III NSCLC in general is
not surprising. Subgroup analysis of stage I - II patients
alone showed that OPN expression was significantly associ-
ated with both relapse free- and overall survival, indicating
that OPN might be a particularly promising biomarker in
early stage NSCLC.Conclusions
This study provides further evidence of the importance
of OPN in the biology of NSCLC. OPN may have the
potential to be used as a biomarker to select patients for
adjuvant treatment following surgical resection, and to
clarify this issue OPN expression in tumors from pa-
tients included in clinical studies on adjuvant chemo-
therapy should be investigated.Additional file
Additional file 1: Figure S1. Expression of OPN in primary NSCLC.
Representative photomicrographs of NSCLC specimens stained with
anti-OPN. Negative, weak and strong staining is demonstrated in A, B
and C, respectively.Competing interests
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